Search

everythinglearnresearchcommunity

for

Search:↓

A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.

Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.

Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

Endocrine therapies for cancer significantly increase the risk of hair loss.

Hair regrowth treatments had modest benefits for patients with long-term hair loss after chemotherapy.

Hormone therapy for breast cancer often leads to sexual issues like vaginal dryness and decreased libido.

Aromatase inhibitor therapy for breast cancer increases the risk of hair loss and thinning.

Some breast cancer treatments, like taxanes, can cause long-term hair loss.

Women generally handle heart enlargement better than men, but it's riskier for them if it occurs; hormones like estrogen offer some protection.

Women have a higher risk of blood clots from hormonal factors and need careful treatment, especially during pregnancy.

Exposure to certain sex hormones can increase health risks, while some hormone therapies may offer benefits for specific conditions.

Menopause often leads to lower sexual desire and discomfort during sex, but treatment should be personalized and only if it bothers the woman.

PCOS may increase the risk of certain cancers.

PCOS is linked to a higher risk of endometrial cancer but not ovarian or breast cancer, and more research is needed on its role in cancer development and treatment effects.

Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.

Intravaginal testosterone cream improves sexual satisfaction and reduces vaginal discomfort in postmenopausal women on breast cancer treatment without affecting hormone levels.

Hormones like androgens, estrogen, thyroid hormones, and stress hormones can contribute to hair loss, and treatments target these hormonal imbalances.

ERβ has potential in treating prostate cancer and neurodegenerative diseases, but human studies are needed before clinical use.

Different types of persistent hair loss after chemotherapy respond differently to treatments.

Scalp cooling effectively prevents severe hair loss in breast cancer patients treated with docetaxel and is safe.

The review recommends hormone replacement therapy for women with premature ovarian insufficiency to manage symptoms and protect health, with specific approaches for different groups.

Hair growth-promoting nutraceuticals do not block the cancer-fighting effects of tamoxifen and may enhance its action.

Certain nutraceuticals may enhance hair growth without affecting the cancer-fighting properties of tamoxifen.

Nutraceuticals that promote hair growth do not reduce tamoxifen's effectiveness in breast cancer treatment.

Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.

Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

Drugs for hormone-related conditions might help treat mental disorders but could have serious side effects.